Abstract
In the area of lead optimization for potential CNS-active drugs in medicinal chemistry, there is a great need for experimental methodologies that can generate data relevant to estimates of free (unbound) drug exposure within the CNS. The methods chosen have to be efficient and have to measure a pharmacologically relevant entity. The lack of methods for generating such data is probably linked with the lack of successful lead optimization strategies within CNS drug discovery. This article evaluates available methods for estimating drug delivery to the brain, and discusses the relevance of the methods from the perspective of CNS exposure to free drug. It is suggested that the extent of drug delivery is the most important investigative parameter, since permeability (rate of transfer) can vary within a relatively wide range and still allow effects within the CNS. Following this suggestion would shift the focus from the current way of thinking and could lead to the development of less lipophilic compounds than are currently being investigated. It is concluded that an extensive collection of quality data on brain drug delivery, transporter affinities and in vivo behavior is urgently required so as to be able to build relevant predictive in vitro and in silico models for the future. These models need to be much more focused on the asymmetry of active transport across the BBB than on permeability data.
Current Topics in Medicinal Chemistry
Title: Methodologies to Assess Brain Drug Delivery in Lead Optimization
Volume: 9 Issue: 2
Author(s): Margareta Hammarlund-Udenaes, Ulf Bredberg and Markus Friden
Affiliation:
Abstract: In the area of lead optimization for potential CNS-active drugs in medicinal chemistry, there is a great need for experimental methodologies that can generate data relevant to estimates of free (unbound) drug exposure within the CNS. The methods chosen have to be efficient and have to measure a pharmacologically relevant entity. The lack of methods for generating such data is probably linked with the lack of successful lead optimization strategies within CNS drug discovery. This article evaluates available methods for estimating drug delivery to the brain, and discusses the relevance of the methods from the perspective of CNS exposure to free drug. It is suggested that the extent of drug delivery is the most important investigative parameter, since permeability (rate of transfer) can vary within a relatively wide range and still allow effects within the CNS. Following this suggestion would shift the focus from the current way of thinking and could lead to the development of less lipophilic compounds than are currently being investigated. It is concluded that an extensive collection of quality data on brain drug delivery, transporter affinities and in vivo behavior is urgently required so as to be able to build relevant predictive in vitro and in silico models for the future. These models need to be much more focused on the asymmetry of active transport across the BBB than on permeability data.
Export Options
About this article
Cite this article as:
Hammarlund-Udenaes Margareta, Bredberg Ulf and Friden Markus, Methodologies to Assess Brain Drug Delivery in Lead Optimization, Current Topics in Medicinal Chemistry 2009; 9 (2) . https://dx.doi.org/10.2174/156802609787521607
DOI https://dx.doi.org/10.2174/156802609787521607 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Mechanisms of Brain Signaling During Sepsis
Current Neuropharmacology Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes
Current Enzyme Inhibition Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design Real-time Polymerase Chain Reaction for Mycobacterium tuberculosis Meningitis is More Sensitive in Patients with HIV Co-Infection
Current HIV Research Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry A Systematic Review and Meta-Analysis of Serotype Distribution of <i>Streptococcus Pneumoniae</i> in Iran: Practical Evidence to Optimizing Local Vaccination Protocols
Infectious Disorders - Drug Targets Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development
Current Drug Discovery Technologies An Update on the Synthesis and Antibacterial Effects of Carbapenems
Recent Patents on Anti-Infective Drug Discovery Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients
Current Pharmaceutical Biotechnology